GlassScriptPhysician profile
April S Gardner
NPI 1780885970
$7,166.76
in general payments reported to CMS, 2019-2025
26 companies · $1,486 in 2025
The $1,486 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $766 · 2022: $1,355 · 2023: $1,914 · 2024: $1,647 · 2025: $1,486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,046.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,045.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,908.12 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $700.34 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $455.25 | 2021-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Lundbeck LLC | $392.40 | 2021-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $385.88 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Neurocrine Biosciences, INC. | $360.64 | 2022-2025 | Ingrezza |
| Astrazeneca Pharmaceuticals LP | $327.94 | 2022-2024 | Fasenra, Airsupra |
| Axsome Therapeutics, INC. | $320.35 | 2023-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $312.60 | 2021-2025 | Uzedy, Austedo, Austedo Xr |
| Vanda Pharmaceuticals INC. | $268.45 | 2022-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $188.18 | 2022-2025 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $180.15 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $168.91 | 2021-2022 | |
| Indivior INC. | $144.14 | 2022-2024 | Perseris, Sublocade |
| Tempus Ai, INC | $124.37 | 2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $113.34 | 2021 | |
| Glaxosmithkline, LLC. | $112.89 | 2022 | |
| Urovant Sciences INC | $112.30 | 2022 | |
| Noven Therapeutics, LLC | $103.29 | 2023-2025 | Secuado, Xelstrym |
| Idorsia Pharmaceuticals US INC | $97.50 | 2022 | |
| Ironshore Pharmaceuticals INC. | $84.52 | 2024 | |
| Esperion Therapeutics, INC. | $79.20 | 2021 | |
| Supernus Pharmaceuticals, INC. | $75.13 | 2025 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $72.51 | 2021-2025 | Trintellix |
| Collegium Pharmaceutical, INC. | $40.46 | 2025 | Jornay Pm |
| Corium, LLC | $37.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Gardner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.